PRINCETON, N.J., June 11 BioWa, Inc. announced today thatit has licensed its POTELLIGENT(R) Technology to Novartis for the developmentof antibody therapeutics with enhanced antibody-dependent cellularcytotoxicity (ADCC).
The license provides Novartis with access to BioWa's POTELLIGENT(R)Technology platform to research, develop, manufacture, and commercializeADCC-enhanced antibodies for an undisclosed number of targets. In return,BioWa will receive license fees, development milestone payments and royaltieson products developed by Novartis. Additional terms were not disclosed.
"POTELLIGENT(R) Technology has shown its clinical benefits in variousclinical trials for oncology and inflammatory diseases," said Dr. MasamichiKoike, President and CEO of BioWa. "We are pleased to make this technologyavailable to a world-wide, industry leader like Novartis. We believe thatthis agreement significantly helps us to maximize the value of POTELLIGENT(R)Technology and to fulfill our mission to bring the benefit of the technologyto patients in need as quickly as possible."
About POTELLIGENT(R) Technology
POTELLIGENT(R) Technology improves potency and efficacy of antibodytherapeutics by enhancing ADCC, one of the major mechanisms of action forantibody therapeutics. POTELLIGENT(R) Technology involves the reduction ofthe amount of fucose in the carbohydrate structure of an antibody using aproprietary fucosyltransferase-knockout CHO cell line as a production cell.Research shows that POTELLIGENT(R) Technology dramatically enhances ADCCactivity of an antibody in vitro, and significantly increases potency andefficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies arebeing investigated in human clinical trials.
About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd.(TSE: 4151), Japan's leading pharmaceutical and largest biotech company, andis the exclusive worldwide licensor of AccretaMab(TM) platform.AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM)Technologies, creating a superior antibody molecule with enhanced ADCC and CDCactivities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologiesto partners under a license to maximize the value of these technologies. Inaddition, BioWa is focused on development of ADCC/CDC enhanced monoclonalantibody-based therapeutics to fight cancer and other life-threatening anddebilitating diseases. Both BioWa and Kyowa have POTELLIGENT(R) antibodyproducts at various clinical stages. For more information about BioWa, visitits web site at http://www.biowa.com.
POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks ofKyowa Hakko Kogyo Co., Ltd. All rights are reserved.
SOURCE BioWa, Inc.